AIM: The role of substance P and the neurokinin-1 receptor (NK-1R) in the transition from inflammation to dysplasia in inflammatory bowel disease is not clear. MATERIALS AND METHODS: Colitis-associated dysplasia was induced in Sprague-Dawley rats by intracolonic, then systemic, administration of trinitrobenzene sulfonic acid. One group of animals received the NK-1R antagonist SR140333; the rest received vehicle. Colons were removed and analyzed for damage and expression of NK-1R downstream components. RESULTS: The NK-1R antagonist-treated animals had significantly reduced macroscopic and microscopic damage and decreased incidence of inflammatory bowel disease. Twice as many of these animals had a normal diagnosis in any region of the colon. A decrease in proliferation index, Cox-2 expression, and active Erk1/2 was found compared with the vehicle-treated group. In Caco-2 cells, Erk1/2 was activated by substance P and prostaglandin E2. CONCLUSION: A selective NK-1R antagonist may delay the development of further colonic damage, offering a potential treatment for patients with long-standing colitis.
AIM: The role of substance P and the neurokinin-1 receptor (NK-1R) in the transition from inflammation to dysplasia in inflammatory bowel disease is not clear. MATERIALS AND METHODS:Colitis-associated dysplasia was induced in Sprague-Dawley rats by intracolonic, then systemic, administration of trinitrobenzene sulfonic acid. One group of animals received the NK-1R antagonist SR140333; the rest received vehicle. Colons were removed and analyzed for damage and expression of NK-1R downstream components. RESULTS: The NK-1R antagonist-treated animals had significantly reduced macroscopic and microscopic damage and decreased incidence of inflammatory bowel disease. Twice as many of these animals had a normal diagnosis in any region of the colon. A decrease in proliferation index, Cox-2 expression, and active Erk1/2 was found compared with the vehicle-treated group. In Caco-2 cells, Erk1/2 was activated by substance P and prostaglandin E2. CONCLUSION: A selective NK-1R antagonist may delay the development of further colonic damage, offering a potential treatment for patients with long-standing colitis.
Authors: I Castagliuolo; O Morteau; A C Keates; L Valenick; C-C Wang; J Zacks; B Lu; N P Gerard; C Pothoulakis Journal: Br J Pharmacol Date: 2002-05 Impact factor: 8.739
Authors: D C Allred; G M Clark; R Elledge; S A Fuqua; R W Brown; G C Chamness; C K Osborne; W L McGuire Journal: J Natl Cancer Inst Date: 1993-02-03 Impact factor: 13.506
Authors: Ines Schwetz; Sylvie Bradesi; James A McRoberts; Marciano Sablad; Jerry C Miller; Huping Zhou; Gordon Ohning; Emeran A Mayer Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-11-13 Impact factor: 4.052
Authors: Raymond A Isidro; Myrella L Cruz; Angel A Isidro; Axel Baez; Axel Arroyo; William A González-Marqués; Carmen González-Keelan; Esther A Torres; Caroline B Appleyard Journal: World J Gastroenterol Date: 2015-02-14 Impact factor: 5.742
Authors: Earl Gillespie; Susan E Leeman; Luisa A Watts; Jennifer A Coukos; Michael J O'Brien; Sandra R Cerda; Francis A Farraye; Arthur F Stucchi; James M Becker Journal: Proc Natl Acad Sci U S A Date: 2011-10-03 Impact factor: 11.205
Authors: Martijn Hofman; Frederik Rabenschlag; Hagen Andruszkow; Julia Andruszkow; Diana Möckel; Twan Lammers; Aneta Kolejewska; Philipp Kobbe; Johannes Greven; Michel Paul Johan Teuben; Martijn Poeze; Frank Hildebrand Journal: Sci Rep Date: 2019-07-05 Impact factor: 4.379